Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 7/20 | 0.53 |
| ▸ | CA2 | P00918 | 7/20 | 0.53 |
| ▸ | CA12 | O43570 | 6/20 | 0.53 |
| ▸ | CA9 | Q16790 | 6/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | STK17B | O94768 | 1/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7282098 | 0.98 | TDP1 (0.67) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL3240917 | 0.98 | TDP1 (0.67) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL7283128 | 0.98 | TDP1 (0.67) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL9215977 | 0.98 | TDP1 (0.67) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL7282335 | 0.98 | TDP1 (0.67) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL17372814 | 0.98 | TDP1 (0.67) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL9225093 | 0.98 | TDP1 (0.67) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL6650033 | 0.95 | TDP1 (0.61) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL2444514 | 0.87 | TDP1 (0.55) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL3020258 | 0.87 | TDP1 (0.81) | TDP1MEN1KMT2AGAAMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0255082-B1 | Renin-inhibiting di- and tripeptides, methods for their production, drugs containing them, and their use | HOECHST AG (DE) | 1993-12-01 | — | — | EP | claimed |
| EP-0410278-A1 | Renin inhibiting aminooligohydroxy-derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-01-30 | — | — | EP | claimed |
| EP-0394829-A1 | Renin-inhibiting dipeptides, process to synthetize them, compositions containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-10-31 | — | — | EP | claimed |
| US-4855286-A | HYPOTENSIVE AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-08 | — | — | US | claimed |
| EP-0255082-A2 | Renin-inhibiting di- and tripeptides, methods for their production, drugs containing them, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-02-03 | — | — | EP | claimed |
| EP-0239874-A2 | Substituted derivatives of 4-amino-3-hydroxy-butyric acid, process for their production, medicines containing them, and their application | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-10-07 | — | — | EP | claimed |
| EP-0230242-A2 | Substituted derivatives of 4-amino-3-hydroxy-butyric acid, process for their production, medicines containing them, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-07-29 | — | — | EP | claimed |
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| US-5712417-A | Inhibitors of retroviral proteases | ABBOTT LABORATORIES (US) | 1998-01-27 | — | — | US | disclosed |
| EP-0435059-B1 | Retroviral protease inhibitors | HOECHST AG (DE) | 1997-11-05 | — | — | EP | disclosed |
| EP-0354522-A1 | Use of alpha-aminoboronic acid derivatives in prevention and treatement of viral diseases | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-02-14 | — | — | EP | disclosed |
| EP-0339483-A2 | Renin inhbiting amino-acid derivatives | MERCK PATENT GmbH (DE) | 1989-11-02 | — | — | EP | disclosed |
| EP-0337334-A2 | Renin-inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1989-10-18 | — | — | EP | disclosed |
| US-4855286-A | HYPOTENSIVE AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-08 | — | — | US | disclosed |
| EP-0315574-A2 | Renin inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-05-10 | — | — | EP | disclosed |
| EP-0310015-A2 | Renin-inhibiting dipeptides, process for their preparation, medicines containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-04-05 | — | — | EP | disclosed |
| EP-0255082-A2 | Renin-inhibiting di- and tripeptides, methods for their production, drugs containing them, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | TDP1 758/4885MEN1 2134/4885KMT2A 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.